NantHealth Inc (NASDAQ:NH)’s share price fell 7% during trading on Friday . The stock traded as low as $0.51 and last traded at $0.53. 2,141,629 shares traded hands during trading, an increase of 747% from the average session volume of 252,720 shares. The stock had previously closed at $0.57.
Separately, Zacks Investment Research raised shares of NantHealth from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Friday, June 21st.
The firm has a market capitalization of $57.80 million, a P/E ratio of -0.30 and a beta of 1.15. The company’s 50-day moving average price is $0.60. The company has a quick ratio of 0.86, a current ratio of 0.87 and a debt-to-equity ratio of 70.81.
Several large investors have recently modified their holdings of the company. Paloma Partners Management Co bought a new stake in shares of NantHealth in the fourth quarter valued at about $31,000. SG Americas Securities LLC bought a new stake in shares of NantHealth in the fourth quarter valued at about $29,000. Finally, Miracle Mile Advisors LLC bought a new stake in shares of NantHealth in the first quarter valued at about $27,000. 4.68% of the stock is currently owned by institutional investors.
NantHealth Company Profile (NASDAQ:NH)
NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.
Featured Story: What are CEFs?
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.